CATHY HOLLOWELL: Open Payments
NPI 1265710941 · MIAMI LAKES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$801 in 34 payments from 11 companies in 2025. Trend: 2023 $253 · 2024 $682 · 2025 $801
Food & beverage: $801
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $216 |
| GENZYME CORPORATION | 7 | $195 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| CSL Behring | 2 | $53 |
| Galderma Laboratories, L.P. | 2 | $38 |
| Lilly USA, LLC | 1 | $27 |
| Optinose US, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
Products named: DUPIXENT, NEFFY, AIRSUPRA, FASENRA, TRELEGY ELLIPTA, NEMLUVIO, TEZSPIRE, TALTZ.
Industry payments across FL — which companies pay providers there.
